Page last updated: 2024-12-11

stemphone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

stemphone: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6441692
CHEMBL ID2288178
MeSH IDM0231669

Synonyms (6)

Synonym
stemphone
[(e,2s,3s)-2-[(3r,4ar,6ar,12s,12as,12br)-12-hydroxy-3-(2-hydroxypropan-2-yl)-6a,12b-dimethyl-8,11-dioxo-1,2,3,4a,5,6,12,12a-octahydropyrano[3,2-a]xanthen-9-yl]-4-methylhex-4-en-3-yl] acetate
cochlioquinone a, 21,22-didehydro-, (21e)-
54854-92-1
CHEMBL2288178
bdbm50529932

Research Excerpts

Treatment

ExcerptReferenceRelevance
"Treatment with stemphone did not affect contractions in these tissues."( Novel diacylglycerol kinase inhibitor selectively suppressed an U46619-induced enhancement of mouse portal vein contraction under high glucose conditions.
Miyatake, M; Momose, K; Nobe, H; Nobe, K; Sakai, Y; Takashima, J, 2004
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Diacylglycerol kinase alphaHomo sapiens (human)Ki3.32002.26002.79003.3200AID1613990
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
phosphatidic acid biosynthetic processDiacylglycerol kinase alphaHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayDiacylglycerol kinase alphaHomo sapiens (human)
platelet activationDiacylglycerol kinase alphaHomo sapiens (human)
diacylglycerol metabolic processDiacylglycerol kinase alphaHomo sapiens (human)
glycerolipid metabolic processDiacylglycerol kinase alphaHomo sapiens (human)
lipid phosphorylationDiacylglycerol kinase alphaHomo sapiens (human)
intracellular signal transductionDiacylglycerol kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (7)

Processvia Protein(s)Taxonomy
ATP-dependent diacylglycerol kinase activityDiacylglycerol kinase alphaHomo sapiens (human)
calcium ion bindingDiacylglycerol kinase alphaHomo sapiens (human)
ATP bindingDiacylglycerol kinase alphaHomo sapiens (human)
phospholipid bindingDiacylglycerol kinase alphaHomo sapiens (human)
lipid bindingDiacylglycerol kinase alphaHomo sapiens (human)
kinase activityDiacylglycerol kinase alphaHomo sapiens (human)
alkylglycerol kinase activityDiacylglycerol kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (3)

Processvia Protein(s)Taxonomy
cytosolDiacylglycerol kinase alphaHomo sapiens (human)
plasma membraneDiacylglycerol kinase alphaHomo sapiens (human)
membraneDiacylglycerol kinase alphaHomo sapiens (human)
plasma membraneDiacylglycerol kinase alphaHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1613990Inhibition of DGKalpha in human erythrocytes using OAG as substrate preincubated for 1 min followed by OAG addition and measured after 8 mins in presence of [gamma-32P]ATP2019European journal of medicinal chemistry, Feb-15, Volume: 164Identification of a novel DGKα inhibitor for XLP-1 therapy by virtual screening.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (9)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (22.22)18.2507
2000's5 (55.56)29.6817
2010's1 (11.11)24.3611
2020's1 (11.11)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other9 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]